Veradermics, Inc.

The exercise price and the number of shares of common stock issuable upon exercise of each Pre-Funded Warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the common stock.

SEC original ↗Veradermics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Available-for-sale debt securities The amortized cost and fair value of our available-for-sale debt securities by type of security as of June 30, 2026 are as follows: (in thousands) Fair Value Hierarchy Level Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Money market funds Level 1 $ 95,644 $ $ $ 95,644 U.

SEC original ↗Veradermics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

government agency securities Level 2 83,761 ( 118 ) 83,643 The amortized cost and fair value of our available-for-sale debt securities by type of security as of December 31, 2025 are as follows: (in thousands) Fair Value Hierarchy Level Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Money market funds Level 1 $ 12,204 $ $ $ 12,204 U.

SEC original ↗Veradermics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

government agency securities Level 2 49,767 15 ( 1 ) 49,781 17 The fair values of available-for-sale debt securities, by classification, included in the condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025 are as follows: (in thousands) As of June 30, 2026 As of December 31, 2025 Cash and cash equivalents $ 314,901 $ 20,203 Marketable securities 500,561 120,097 As of June 30, 2026 and December 31, 2025, the amounts shown for marketable securities on our condensed consolidated balance sheets are inclusive of $ 3.7 million and $ 0.9 million of earned interest receivable, respectively.

SEC original ↗Veradermics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The fair value of available-for-sale debt securities as of June 30, 2026 and December 31, 2025, by contractual maturity, are summarized as follows: As of June 30, 2026 As of December 31, 2025 (in thousands) Amortized Cost Fair Value Amortized Cost Fair Value Due in one year or less $ 656,055 $ 655,768 $ 114,003 $ 114,047 Due in one year through five years 160,303 159,694 26,237 26,253 Total $ 816,358 $ 815,462 $ 140,240 $ 140,300 The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of June 30, 2026 and December 31, 2025 was $ 590.7 million and $ 9.6 million, respectively.

SEC original ↗Veradermics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

As of June 30, 2026 and December 31, 2025, the Company believes that the cost basis of our available-for-sale debt securities is recoverable and no allowance for credit losses was recorded.

SEC original ↗Veradermics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

19, 2026-- Veradermics, Incorporated (NYSE MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from Part A of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study 304 ) evaluating VDPHL01, a proprietary, extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss.

SEC original ↗Veradermics, Inc. — Earnings release (8-K exhibit)EX-99Oct 19, 2026

Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss.

SEC original ↗Veradermics, Inc. — Earnings release (8-K exhibit)EX-99Oct 19, 2026

Chief Executive Officer, Veradermics Mark Neumann Chief Commercial & Strategy Officer, Veradermics Dominic Carrano Chief Financial Officer, Veradermics Michael Payette, M.

SEC original ↗Veradermics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 19, 2026

In some cases, you can identify forward-looking statements because they contain words such as may, will, shall, should, expect, plan, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, potential or continue or the negative of these words or other similar expressions that concern our expectations, strategy, plans or intentions, although not all forward-looking statements are accompanied by such words.

SEC original ↗Veradermics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 19, 2026

Co-Founder, Central Connecticut Dermatology 31 OCTOBER 2026 Study '304' Clinical Trial Topline: Results from Market Opinion Study October 2026 Presented by: Mark Neumann, Chief Commercial and Strategy Officer OCTOBER 2026 33 Objective: understand whether the VDPHL01 Phase 3 male PHL profile will substantially grow the prescription market by expanding and deepening the prescriber base.

SEC original ↗Veradermics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 19, 2026

We have had limited advances in prescription treatments for pattern hair loss, and achieving patients treatment goals remains a challenge.

SEC original ↗Veradermics, Inc. — Earnings release (8-K exhibit)EX-99Oct 19, 2026

Forward-Looking Statements This press release contains forward-looking statements, which involve risks, uncertainties and contingencies, many of which are beyond the control of Veradermics, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements.

SEC original ↗Veradermics, Inc. — Earnings release (8-K exhibit)EX-99Oct 19, 2026

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Veradermics control, these forward-looking statements should not be relied upon as guarantees of future events.

SEC original ↗Veradermics, Inc. — Earnings release (8-K exhibit)EX-99Oct 19, 2026

New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties.

SEC original ↗Veradermics, Inc. — Earnings release (8-K exhibit)EX-99Oct 19, 2026

Co-Founder, Central Connecticut Dermatology MANE Speakers Joined by OCTOBER 2026 This presentation contains forward-looking statements that involve substantial risks and uncertainties.

SEC original ↗Veradermics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 19, 2026

Disclaimer 4 Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or other events to be materially different from any future results, performance or other events expressed or implied by the forward-looking statements, including the risks and uncertainties identified in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the period ended June 30, 2026, and subsequent filings with the U.

SEC original ↗Veradermics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Oct 19, 2026